PRO-PHARMACEUTICALS REPORTS ENROLLMENT PROGRESS IN COLORECTAL CANCER TRIAL

Pro-Pharmaceuticals has announced that 10 patients have been enrolled at three clinical sites in the U.S. in Stage l of its Phase ll metastatic colorectal cancer trial with Davanat/5-FU. In this trial, the company expects to enroll up to 15 patients in Stage l. Davanat is a proprietary polysaccharide that target-delivers chemotherapy drugs to protein receptors (lectins) that are specific to cancer cells.

In the study, patients with metastatic colorectal cancer, which has spread despite treatment with approved therapies, are receiving Davanat/5-FU in monthly cycles for at least two cycles or until their disease progresses. These patients are refractory to 5-FU and have a minimum of 12 weeks to live. Dosing of patients began in May 2005.